Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACON NASDAQ:BGLC NASDAQ:BRTX NASDAQ:KDLY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONAclarion$7.62+2.0%$7.75$6.20▼$3,499.51$4.35M1.4399,954 shs82,946 shsBGLCBioNexus Gene Lab$5.19-4.2%$5.36$2.01▼$15.60$9.74M5.2103,415 shs19,736 shsBRTXBiorestorative Therapies$1.58-1.6%$1.56$1.19▼$2.55$12.77M-0.6973,360 shs16,063 shsKDLYKindly MD$0.72-4.3%$3.85$0.65▼$34.77$4.34MN/A2.29 million shs15.78 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONAclarion+2.01%-12.41%-5.34%+2.01%-99.55%BGLCBioNexus Gene Lab-4.24%+0.58%-1.33%+5.92%+41.22%BRTXBiorestorative Therapies-1.56%-0.32%+8.62%-2.78%-1.56%KDLYKindly MD-4.26%-9.99%-45.86%-93.39%-35.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONAclarion$7.62+2.0%$7.75$6.20▼$3,499.51$4.35M1.4399,954 shs82,946 shsBGLCBioNexus Gene Lab$5.19-4.2%$5.36$2.01▼$15.60$9.74M5.2103,415 shs19,736 shsBRTXBiorestorative Therapies$1.58-1.6%$1.56$1.19▼$2.55$12.77M-0.6973,360 shs16,063 shsKDLYKindly MD$0.72-4.3%$3.85$0.65▼$34.77$4.34MN/A2.29 million shs15.78 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONAclarion+2.01%-12.41%-5.34%+2.01%-99.55%BGLCBioNexus Gene Lab-4.24%+0.58%-1.33%+5.92%+41.22%BRTXBiorestorative Therapies-1.56%-0.32%+8.62%-2.78%-1.56%KDLYKindly MD-4.26%-9.99%-45.86%-93.39%-35.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACONAclarion 1.50Reduce$11,758.50154,211.02% UpsideBGLCBioNexus Gene Lab 1.00SellN/AN/ABRTXBiorestorative Therapies 1.00SellN/AN/AKDLYKindly MD 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ACON, KDLY, BRTX, and BGLC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ACONAclarionWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025BGLCBioNexus Gene LabWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025BRTXBiorestorative TherapiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ACONAclarionWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BGLCBioNexus Gene LabWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025BRTXBiorestorative TherapiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACONAclarion$62.95K70.45N/AN/A$51.50 per share0.15BGLCBioNexus Gene Lab$9.51M0.98N/AN/A$4.63 per share1.12BRTXBiorestorative Therapies$400K31.42N/AN/A$1.23 per share1.28KDLYKindly MD$2.47M1.76N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACONAclarion-$6.99MN/A0.00N/AN/A-11,238.59%-83.63%-76.55%11/13/2025 (Estimated)BGLCBioNexus Gene Lab-$1.60MN/A0.00∞N/A-30.70%-35.54%-29.08%N/ABRTXBiorestorative Therapies-$8.98M-$1.27N/AN/AN/A-1,772.40%-137.00%-88.31%11/11/2025 (Estimated)KDLYKindly MDN/A-$0.77N/A∞N/AN/AN/AN/AN/ALatest ACON, KDLY, BRTX, and BGLC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ACONAclarion-$2.64N/AN/AN/AN/AN/A11/11/2025Q3 2025BRTXBiorestorative Therapies-$0.38N/AN/AN/AN/AN/A8/18/2025Q2 2025BGLCBioNexus Gene LabN/A-$0.34N/A-$0.34N/A$2.26 million8/14/2025Q2 2025ACONAclarion-$2.26-$2.75-$0.49-$2.75$0.03 million$0.02 million8/12/2025Q2 2025BRTXBiorestorative Therapies-$0.41-$0.30+$0.11-$0.30$0.34 million$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACONAclarionN/AN/AN/AN/AN/ABGLCBioNexus Gene LabN/AN/AN/AN/AN/ABRTXBiorestorative TherapiesN/AN/AN/AN/AN/AKDLYKindly MDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACONAclarionN/A23.8323.83BGLCBioNexus Gene LabN/A3.632.94BRTXBiorestorative TherapiesN/A2.072.07KDLYKindly MDN/A5.435.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACONAclarion7.52%BGLCBioNexus Gene Lab18.85%BRTXBiorestorative Therapies69.38%KDLYKindly MDN/AInsider OwnershipCompanyInsider OwnershipACONAclarion0.77%BGLCBioNexus Gene Lab0.70%BRTXBiorestorative Therapies30.80%KDLYKindly MD50.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACONAclarion7582,000578,000Not OptionableBGLCBioNexus Gene Lab301.80 million1.78 millionNot OptionableBRTXBiorestorative Therapies77.98 million5.52 millionNot OptionableKDLYKindly MDN/A6.02 million2.96 millionN/AACON, BRTX, BGLC, and KDLY HeadlinesRecent News About These CompaniesKindly MD (NASDAQ:KDLY) Trading Down 4.3% - Here's Why4 hours ago | americanbankingnews.comWhat Happened With Bitcoin Treasury Kindly MD Stock Today?September 9, 2025 | benzinga.comReed Smith Advises Anthony Pompliano and ProCap Financial in Historic $750 million Bitcoin Treasury RaiseJune 23, 2025 | prnewswire.comNAKA Kindly MD, Inc.May 31, 2025 | seekingalpha.comNakamoto Holdings, Kindly MD, Anchorage Digital Announce Strategic Bitcoin Treasury PartnershipMay 26, 2025 | crowdfundinsider.comCKindly MD Changes Ticker Symbols Amid MergerMay 23, 2025 | tipranks.comAnchorage Digital named exclusive custodian for KindlyMD Bitcoin assetsMay 22, 2025 | investing.comKindlyMD Stock Soars After Shareholders Approve Bitcoin Treasury Strategy With Nakamoto Merger Led By Trump Crypto AdvisorMay 21, 2025 | msn.comNakamoto Holdings, Kindly MD, and Anchorage Digital Form Strategic Bitcoin Treasury PartnershipMay 21, 2025 | accessnewswire.comAKindlyMD Shareholders Approve Proposed Merger with Nakamoto HoldingsMay 21, 2025 | finanznachrichten.deKindlyMD shareholders approve Nakamoto mergerMay 21, 2025 | investing.comSurprising stock jumps over 30% after SEC confirms mergerMay 21, 2025 | msn.comKindlyMD® Shareholders Approve Proposed Merger with Nakamoto HoldingsMay 20, 2025 | businesswire.comKindly MD, Inc. Updates Executive Employment AgreementsMay 16, 2025 | tipranks.comKindlyMD Wants to Become the Next MicroStrategy. Should You Buy KDLY Stock Now for Its Bitcoin Treasury and Trump Ties?May 15, 2025 | msn.comKindlyMD Skyrockets on Merger With Nakamoto to Make Bitcoin TreasuryMay 13, 2025 | marketwatch.comKindlyMD, Nakamoto Holdings to Merge, Pursue Global Bitcoin Treasury Strategy, Shares Rocket HigherMay 12, 2025 | crowdfundinsider.comCNakamoto Holdings Raises $710M, Merges With KindlyMD To Build Bitcoin Treasury Holding CompanyMay 12, 2025 | benzinga.comTarget, Astera Labs, Kindly MD: Trending TickersMay 12, 2025 | finance.yahoo.comKindlyMD Stock Surges To All-Time High After Announcing Merger With Nakamoto To Launch Bitcoin Treasury StrategyMay 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACON, BRTX, BGLC, and KDLY Company DescriptionsAclarion NASDAQ:ACON$7.62 +0.15 (+2.01%) Closing price 10/23/2025 03:58 PM EasternExtended Trading$7.53 -0.09 (-1.18%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.BioNexus Gene Lab NASDAQ:BGLC$5.19 -0.23 (-4.24%) Closing price 10/23/2025 03:59 PM EasternExtended Trading$5.19 0.00 (0.00%) As of 06:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.Biorestorative Therapies NASDAQ:BRTX$1.58 -0.03 (-1.56%) Closing price 10/23/2025 03:55 PM EasternExtended Trading$1.57 0.00 (-0.25%) As of 10/23/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Kindly MD NASDAQ:KDLY$0.72 -0.03 (-4.26%) As of 10/22/2025Kindly MD, Inc. provides healthcare services. Its services include medication management, behavioral healthcare and alternative treatments. The firm offers evaluation and management, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy. The company was founded by Timothy Pickett in December 2019 and is headquartered in Murray, UT. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
